Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iPAVE – imaging Pituitary Activation by Exendin
2018-003566-13Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2018
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of 68Ga-NODAGA-Exendin-4 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Pituitary uptake of 68Ga-NODAGA-exendin. Started Oct 2018; status: completed.
02
Drugs
68Ga-NODAGA-Exendin-4
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2018-003566-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003566-13.